A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wang, Xiao Fei ^a,b   Feng, Yun ^a   Chen, Ying ^a   Gao, Bei Li ^a   Han, Bao Hui ^b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; OLANZAPINE;

CHEMICALLY INDUCED; HUMAN; META ANALYSIS; NAUSEA; RISK; TREATMENT OUTCOME; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; HUMANS; NAUSEA; ODDS RATIO; TREATMENT OUTCOME; VOMITING;

EID: 84899623340     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04813     Document Type: Article

References (22)

1. Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M. & Herrstedt, J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 24, 4472-4478 (2006). (Pubitemid 46630986)
2. Osoba, D. et al. Effect of postchemotherapy nausea and vomiting on healthrelated quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer. 5, 307-333 (1997).
3. Ettinger, D. S. et al. Antiemesis. J Natl Compr Canc Netw. 10, 456-485 (2012).
4. Hesketh, P. J. Chemotherapy-induced nausea and vomiting. N Engl J Med. 358, 2482-2494 (2008).
5. Herrstedt, J. & Dombernowsky, P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 101, 143-150 (2007). (Pubitemid 47256390)
6. Fulton, B. & Goa, K. L. Olanzapine: are view of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 53, 281-298 (1997). (Pubitemid 27073117)
7. Bymaster, F. P. et al. Radioreceptor binding profile of the atypic alantipsychotic olanzapine. Neuropsychopharmacology. 14, 87-96 (1996). (Pubitemid 26053226)
8. Khojainova, N., Santiago-Palma, J., Kornick, C., Breitbart, W. & Gonzales, G. R. Olanzapine in the management of cancer pain. J. Pain Symptom Manage. 23, 546-550 (2002).
9. Mizukami, N. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J. Pain Symptom Manage. 47, 542-550 (2014).
10. Navari, R. M., Gray, S. E. & Kerr, A. C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 9, 188-195 (2011).
11. Tan, L. et al. Clinical research of Olanzapine for prevention of chemotherapyinduced nausea and vomiting. J Exp Clin Cancer Res. 28, 131(2009).
12. Wang, X. & Wang, L. Effectiveness of olanzapine in prevention of chemotherapyinduced nausea and vomiting. Clin J Clinicians (Electronic Edition). 6, 7406-7407 (2012).
13. Mao, W. K. & Peng, L. Clinical observation of Olanzapine combined with Granisetrom and Hexadecadrol prevent nausea vomit induced by chemoradiontherapy. Chinese Journal of Medicine Guide. 13, 452-454 (2011).
14. Lu, Y. L. et al. Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Clin J Cancer Prev Treat. 20, 544-554 (2013).
15. Jackson, W. C. & Tavernier, L. Olanzapine for intractable nausea in palliative care patients. J. Palliative Med. 6, 251-255 (2003). (Pubitemid 36538899)
16. Licup, N. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 27, 432-434 (2010).
17. Pirl, W. F. & Roth, A. J. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology. 9, 84-87 (2010).
18. Jackson, W. C. & Tavernier, L. Olanzapine for intractable nausea in palliative care patients. J. Palliative Med. 6, 251-255 (2003). (Pubitemid 36538899)
19. Passik, S. D. et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced pain and cancer. J. Pain Symptom Manage. 2, 526-532 (2002). (Pubitemid 34627037)
20. Passik, S. D. et al. Aphase I trial of olanzapine for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest. 22, 383-388 (2004). (Pubitemid 39310908)
21. Navari, R. M. Prevention of emesis from multiple-day chemotherapy regimens. J Nat Compr Cancer Netw. 5, 51-59 (2007). (Pubitemid 46212277)
22. Allison, D. B. & Casey, D. E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 62, 22-31 (2001). (Pubitemid 32402182)